Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis A vaccination: schedule for accelerated immunization.

R Müller1, H Chriske, F Deinhardt

  • 1Medizinische Hoschschule Hannover, Germany.

Vaccine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of human T-cell lymphotropic virus infections in Germany.

Journal of medical virology·1994
Same author

[A new variant of the simian T-lymphotropic retrovirus type I (STLV-IF) in the Sukhumi colony of hamadryas baboons].

Voprosy virusologii·1993
Same author

Production of human cloned antibodies specific for hepatitis D virus-encoded small and large protein.

Journal of hepatology·1993
Same author

Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.

Vaccine·1993
Same author

The immune response to different doses of inactivated hepatitis A vaccine.

Journal of hepatology·1993
Same author

Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis.

The New England journal of medicine·1992
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
See all related articles

The Hepatitis A vaccine (HAV) demonstrated high efficacy and tolerability across various schedules. A two-dose regimen with 720 ELISA units (El.U) achieved superior antibody levels, suggesting potential to replace immune globulin.

Area of Science:

  • Immunology
  • Vaccinology

Background:

  • Hepatitis A virus (HAV) infection is a significant public health concern.
  • Effective vaccination strategies are crucial for preventing HAV transmission.

Purpose of the Study:

  • To evaluate the immunogenicity and tolerability of the Hepatitis A vaccine (strain HM175).
  • To compare different vaccination schedules and antigen doses.
  • To assess the potential of the vaccine as an alternative to immune globulin therapy.

Main Methods:

  • Prospective multicentre trial.
  • Evaluation of vaccination schedules: days 0 and 14 (720 El.U), days 0 and 28 (720 El.U), and days 0 and 28 (360 El.U).
  • Measurement of seroconversion rates and geometric mean concentrations of antibody to HAV (anti-HAV).

Related Experiment Videos

Main Results:

  • All tested vaccination schedules achieved high seroconversion rates (95-100%) after two doses.
  • The vaccine containing 720 El.U of HAV antigen resulted in higher anti-HAV geometric mean concentrations.
  • The vaccine was well-tolerated across all study groups.
  • An abbreviated schedule (days 0 and 14 with 720 El.U) yielded 100% seroconversion by day 28 with antibody levels exceeding those from passive immunization.

Conclusions:

  • The Hepatitis A vaccine (strain HM175) is highly immunogenic and well-tolerated.
  • A 720 El.U antigen dose is more effective in generating higher antibody titers.
  • An abbreviated vaccination schedule (days 0 and 14) is a viable option, potentially replacing immune globulin administration.
  • This vaccine offers a promising alternative for Hepatitis A prophylaxis.